LifeShield Medical Secures Over RMB 100 Million in New Funding to Advance Cardiovascular and Respiratory Therapies

Oct 10, 2023 00:00 CST Updated 00:00

LifeShield

Innovative Medical Device R&D and Manufacturer

Source of the article:Heart NotCome;Editor:Zhang Yuqing

Reprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.

Heart Future

Recently,LifeShield Medical (hereinafter referred to as "LifeShield")Announced the successful completion of an over 100-million-yuan financing round. This round of funding will be used for the construction of its interventional artificial heart system project factory, to accelerate the clinical validation and commercialization process of ECMO, and to further advance the clinical validation of China's first carbon dioxide removal system for treating severe chronic obstructive pulmonary disease (COPD).

# Market Overview

As China's aging population intensifies,The prevalence of heart failure continues to grow,The number of heart failure patients in China exceeds tens of millions each year,ButThere is a lack of effective treatment options in clinical practice.

In China, 1.3 million patients with coronary heart disease undergo PCI surgery every year, of which 30% (nearly 400,000) high-risk patients require intraoperative protection. Moreover, nearly 350,000 patients with cardiogenic shock die each year in China due to lack of timely treatment or effective therapies.

For high-risk PCI and cardiogenic shock, pVAD therapy has been successfully applied in over 250,000 cases abroad, with its safety and effectiveness widely validated.But this innovative technology and related products have not yet been introduced into China, leaving the domestic market completely blank.

Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death globally and one of the four major chronic diseases in China.A recent epidemiological survey data shows that there are 100 million COPD patients in China, with a heavy disease burden and a lack of effective treatment methods.

As COPD progresses, patients experience dyspnea, leading to carbon dioxide retention in the bloodstream, which not only affects normal ventilation function but also causes multiple complications.Therefore, in the treatment of COPDA Crucial LinkIt is to remove carbon dioxide from the patient's blood and protect the patient's lungs from further damage.

In recent years, ECCO2R (artificial lung) designed for ECMO systems has been used clinically to remove carbon dioxide. However, the lack of targeted design in aspects such as system configuration and vascular pathways may lead to complications like thrombosis.

# Product Introduction

LifeShield's core product pipeline leverages its globally leading blood pump platform technology, focusing on the heart and lungs.Innovative therapies in the field of organ failure, with a product pipeline including:

Next-Generation Percutaneous Ventricular Assist Device (pVAD) System:

LifeShield’s pVAD product is designed for the most widely used and largest golden flow market, achieving independent innovation through an innovative "non-perfusion" sealing design.

At the same time, based on the team's extensive R&D experience, LifeShield optimized the flow field design of the key component of the pVAD product—the high-speed impeller—improving the operational efficiency and hemocompatibility of the interventional pump.

In previous animal experiments, it has been successfully verified that the hemolysis level is far below the clinically relevant value, no blood clots or thrombosis have formed in the critical parts of the interventional pump, and no major clinical complications have been recorded.

Moreover, LifeShield effectively reduces the size of pVAD products by optimizing components and the overall design of the pVAD product, allowing it to be operated in catheterization labs and operating rooms, significantly improving clinical operational convenience and safety.

China's First Stacked Membrane ECMO Oxygenator:

LifeShield's ECMO oxygenator adoptsThe "stacked membrane" design, a first in China,And further optimize the flow field design, the transmembrane pressure difference of the oxygenator is only 38mmHg (5L), reducing blood cell damage, and featuring higher gas exchange and heat exchange efficiency.

At the same time, LifeShield effectively reduces the volume of the blood pump, achieves a smaller priming volume, improves pump head stability, and enhances hemolysis indicators.

At the beginning of this year, LifeShield's ECMO systemHas successfully completed the registered animal trial,All experimental sheep successfully reached the 16-day clinical endpoint under relevant V-V and V-A modes, achieving a 100% survival rate. Currently, LifeShield's ECMO product is undergoing registrational clinical trials in humans, showing significant clinical effects and receiving high praise from clinicians.

Carbon Dioxide Removal System (ECCO2R):

Chronic Obstructive Pulmonary Disease (COPD) isThe third leading cause of death globally and one of the four major chronic diseases in China,ThereforeIt is crucial to develop a truly ECCO2R designed for COPD patients.

The ECCO2R oxygenator developed by LifeShield is specifically designed with an optimal flow range for treating COPD. It can effectively remove high concentrations of carbon dioxide retained in the blood of COPD patients, while achieving high levels of carbon dioxide removal and oxygen transfer rates.

# Company Introduction

LifeShield is a Sino-German multinational medical device company,Focused on the research, development, and production of interventional left ventricular assist systems, extracorporeal blood pumps, and extracorporeal artificial oxygenation systems, etc.,And used to treat diseases of the heart, brain, lungs, liver, and kidneys, committed to providing medical technology solutions for patients, thereby ensuring their physical health.

Company's PredecessorLifeshield Medical (Suzhou)Founded in 2018, Lifeshield Medical is a startup company focused on the field of internal and external life support. Through research, development, and technological innovation, it is dedicated to providing high-quality products and treatment solutions for patients with cardiovascular diseases and respiratory failure.

The innovative technology of LifeShield originated in Aachen, Germany. In 2011, Dr. Tim Kaufmann, a professor at RWTH Aachen University, and his mentor, Professor Ulrich Steinseifer, co-founded Enmodes in Aachen, Germany, focusing on providing development services for medical devices and instruments.

LifeShield has absorbed the advanced technology and R&D experience of the German team, while leveraging China's efficient, fast-paced work ethic and its unique cost advantages to transform technology into products.

According to available data, Lifeshield Medical owns two wholly-owned subsidiaries: Enmodes GmbH in Germany and Lifeshield Medical (Suzhou). Enmodes GmbH serves as the global R&D center and is responsible for the European market expansion; Lifeshield Medical (Suzhou) is responsible for the R&D of some products, the global production base, and the market expansion in Greater China.

As of the date of this report, the company's financing history is as follows:

Overseas Cardiovascular Devices:

Products of Chinese Cardiovascular Companies: